GFM
TRDA icon

GF Fund Management’s Entrada Therapeutics TRDA Stock Holding History

GF Fund Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8K Buy
852
+101
+13% +$1.16K ﹤0.01% 554
2025
Q4 		$7.72K Sell
751
-56
-7% -$472 ﹤0.01% 600
2025
Q3 		$4.68K Sell
807
-151
-16% -$883 ﹤0.01% 611
2025
Q2 		$6.44K Hold
958
– – ﹤0.01% 611
2025
Q1 		$8.66K Buy
958
+173
+22% +$2.16K ﹤0.01% 582
2024
Q4 		$13.6K Buy
+785
New +$14.2K ﹤0.01% 508

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GF Fund Management's TRDA Position: Q1 2026 in Review

GF Fund Management increased its Entrada Therapeutics (TRDA) stake by 13% in Q1 2026, buying an estimated $1.16K and bringing the position to 852 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #554.

GF Fund Management first reported a position in TRDA in Q4 2024 and has held it in 6 quarters since. The position peaked at $13.6K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • GF Fund Management held 852 shares of Entrada Therapeutics worth $10.8K as of Q1 2026.
  • GF Fund Management bought 101 Entrada Therapeutics shares in Q1 2026, an estimated $1.16K.
  • Entrada Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #554 holding.
  • GF Fund Management first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Entrada Therapeutics position peaked at $13.6K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.